首页 > 分享 > Ginkgo Bioworks收购三家公司，以增强人工智能和基因编辑能力

Ginkgo Bioworks收购三家公司，以增强人工智能和基因编辑能力

花匠小妙招
2025-04-11 08:49

Ginkgo Bioworks has acquired a biotechnology startup co-founded by gene editing pioneer Feng Zhang, part of the cell engineering company’s plan to build up technologies that can help other companies make genetic medicines.

银杏生物工程（Ginkgo Bioworks）收购了一家由基因编辑先驱张峰（Feng Zhang）共同创立的生物技术初创公司，这是该细胞工程公司建立技术以帮助其他公司制造基因药物计划的一部分。

Through the deal announced Wednesday, Ginkgo will acquire Proof Diagnostics, a biotech Zhang formed in 2020 to develop a fast- low-cost test to detect the virus that causes COVID-19. The companies didn’t disclose financial terms.

通过周三宣布的协议，银杏将收购Proof Diagnostics，这是一家成立于2020年的生物技术公司，旨在开发一种快速低成本的检测方法，以检测导致新型冠状病毒的病毒。这些公司没有披露财务条款。

Proof is one of a handful of startups, among them Mammoth Biosciences and Sherlock Biosciences, that launched in recent years to use gene editing tools to make diagnostic tests. The company was launched by Zhang — who’s helped start multiple gene editing startups, among them Editas Medicine and Beam Therapeutics — as well as MIT scientists Omar Abudayyeh and Jonathan Gootenberg, and Sid Shenai.

Proof是近年来推出的利用基因编辑工具进行诊断测试的少数初创公司之一，其中包括Mammoth Biosciences和Sherlock Biosciences。该公司是由张创办的，他帮助创办了多家基因编辑初创公司，其中包括Editas Medicine和Beam Therapeutics，以及麻省理工学院的科学家奥马尔·阿布戴耶（OmarAbudayyeh）、乔纳森·古腾堡（JonathanGootenberg）和希德·谢奈（SidShenai）。

The group started Proof to address “an emergent need: combating the COVID-19 pandemic,” according to the company’s website.

根据该公司的网站，该组织开始证明“迫切需要：抗击新型冠状病毒大流行”。

Proof submitted an emergency use authorization request to the Food and Drug Administration in 2022 for its COVID-19 test, but hasn’t provided a public update about the diagnostic or its technology since.

证明于2022年向美国食品和药物管理局提交了一份紧急使用授权申请，要求其进行新型冠状病毒肺炎检测，但自那以来，该机构一直没有提供有关该诊断或其技术的公开更新。

In the meantime, the tools Proof harnessed to develop that test have drawn Ginkgo’s attention. The company owns libraries of DNA-cutting enzymes that can be used in gene editing experiments. Those enzymes, called OMEGAs, are “smaller and more diverse” than many others used in gene editing, which could make them easier to deliver into cells, Ginkgo said in a statement.

与此同时，开发该测试所使用的工具引起了银杏的注意。该公司拥有DNA切割酶库，可用于基因编辑实验。银杏在一份声明中说，这些被称为欧米茄的酶比许多其他用于基因编辑的酶“更小、更多样化”，这可能使它们更容易传递到细胞中。

They, along with Proof’s associated intellectual property, are the main focus of Ginkgo’s acquisition.

他们，连同证据的相关知识产权，是银杏收购的主要焦点。

“Integrating Proof’s technologies and libraries gives our customers a new tool to overcome the limitations of current gene editing systems,” Jason Kelly, Ginkgo’s CEO, said in a statement.

银杏首席执行官杰森·凯利（JasonKelly）在一份声明中表示：“整合Proof的技术和文库为我们的客户提供了一种新工具，可以克服当前基因编辑系统的局限性。”

For Ginkgo, the deal is part of a broader push to acquire technology platforms other biotechs can use to make genetic medicines. In 2023, the company acquired startup StrideBio to get access to a way of discovering and engineering the capsids, which deliver the complex treatments. Ginkgo also has a collaboration with Arbor Biotechnologies to create precise editing tools and, on Wednesday, acquired Patch Biosciences, which is using artificial intelligence to design genetic medicines.

对于银杏来说，这笔交易是收购其他生物技术可用于制造基因药物的技术平台的更广泛努力的一部分。2023年，该公司收购了初创公司StrideBio，以获得一种发现和设计衣壳的方法，从而提供复杂的治疗方法。银杏还与Arbor Biotechnologies合作创建精确的编辑工具，并于周三收购了Patch Biosciences，该公司正在使用人工智能设计基因药物。

Boston-based Ginkgo went public in 2021 by merging with a special purpose acquisition company, or SPAC, that valued it at $15 billion. However, shares have lost more than 85% of their value since, and closed at less than $2 apiece on Tuesday.

总部位于波士顿的银杏于2021年通过与一家特殊目的收购公司（SPAC）合并而上市，该公司的估值为150亿美元。然而，自那以来，股价已下跌逾85%，周二收于每股不到2美元。

The company separately acquired privately held AI drug discovery biotech Reverie Labs on Wednesday as well. Terms weren’t disclosed.

周三，该公司还分别收购了私人持有的AI药物发现生物技术Reverie实验室。条款没有透露。